Decreases in different Dnmt3b activities drive distinct development of hematologic malignancies in mice

Katarina Lopusna1,2, Pawel Nowialis1,4, Jana Opavska3, Ajay Abraham1, Alberto Riva5, Staci L. Haney3, and Rene Opavsky1,*‡

From the 1Department of Anatomy and Cell Biology, University of Florida College of Medicine, Gainesville, Florida, USA; 2ICBR Bioinformatics, Cancer and Genetics Research Complex, University of Florida, Gainesville, Florida, USA; and 3Department of Internal Medicine, University of Nebraska Medical Center, 985950 Nebraska Medical Center, Omaha, Nebraska, USA

Edited by Eric Fearon

DNA methylation regulates gene transcription and is involved in various physiological processes in mammals, including development and hematopoiesis. It is catalyzed by DNA methyltransferases including Dnmt1, Dnmt3a, and Dnmt3b. For Dnmt3b, its effects on transcription can result from its own DNA methylase activity, the recruitment of other Dnmts to mediate methylation, or transcription repression in a methylation-independent manner. Low-frequency mutations in human DNMT3B are found in hematologic malignancies including cutaneous T-cell lymphomas, hairy cell leukemia, and diffuse large B-cell lymphomas. Moreover, Dnmt3b is a tumor suppressor in oncogene-driven lymphoid and myeloid malignancies in mice. However, it is poorly understood how the different Dnmt3b activities contribute to these outcomes. We modulated Dnmt3b activity in vivo by generating Dnmt3b+/− mice expressing one wild-type allele as well as Dnmt3b+/-CI and Dnmt3b+/CI mice where one or both alleles express catalytically inactive Dnmt3bCI. We show that 43% of Dnmt3b+/− mice developed T-cell lymphomas, chronic lymphocytic leukemia, and myeloproliferation over 18 months, thus resembling phenotypes previously observed in Dnmt3a+/- mice, possibly through regulation of shared target genes. Interestingly, Dnmt3b+/-CI and Dnmt3b+/CI mice survived postnatal development and were affected by B-cell rather than T-cell malignancies with decreased penetrance. Genome-wide hypomethylation, increased expression of oncogenes such as Jdp2, STAT1, and Trip13, and p53 downregulation were major events contributing to Dnmt3b+/− lymphoma development. We conclude that Dnmt3b catalytic activity is critical to prevent B-cell transformation in vivo, whereas accessory and methylation-independent repressive functions are important to prevent T-cell transformation.

DNA methylation is an epigenetic modification that contributes to a regulation of gene transcription in mammalian cells. Its association with H3K9me3 and H3K27me3 histone modifications in gene promoters results in gene repression (1, 2). Methylation can also enhance transcription by promoting more efficient binding of transcription factors to their recognition sites (3, 4) and by restricting the activation of alternative promoters within gene bodies (5). DNA methylation is involved in regulation of normal development, differentiation, X chromosome inactivation, and genomic imprinting. It also participates in hematopoiesis, and its deregulation contributes to the pathogenesis of immune disorders, hematologic malignancies, and cancer (5–8).

Four catalytically active enzymes (Dnmt1, Dnmt3a, Dnmt3b, and Dnmt3c) and one catalytically inactive cofactor (Dnmt3L) belong to the family of DNA methyltransferases (Dnmts) in mice. All Dnmts contribute to genome-wide methylation with Dnmt1 considered to be the main maintenance enzyme while Dnmt3a and Dnmt3b primarily involved in de novo activities (9–11). Dnmt3L lacks catalytic activity (CA) but is critical for de novo methylation by linking Dnmt3a and Dnmt3b to chromatin through unmethylated H3 lysine 4 (12). Dnmt3c suppresses transposon activity specifically in male germ cells (13). Dnmts also repress transcription independently of methylation, e.g., through association with histone deacetylases (14–16). Another activity associated with Dnmt3L and Dnmt3b is accessory function (AF) that consists of the ability to recruit other Dnmts to genomic loci to catalyze methylation (12, 17, 18).

Dnmt3b participates in de novo and maintenance methylation, repression of germ line genes, X chromosome inactivation, and its knockout in mice is embryonically lethal (9, 10). In addition to methylation of various genomic elements, Dnmt3b also binds to the bodies of actively transcribed genes through the interaction of its PWWP domain with histone H3 trimethylated at lysine 36 and plays a role in their preferential methylation in embryonic stem cells (19). Human DNMT3B is causatively linked to the immunodeficiency-centromeric instability-facial anomalies (ICF) syndrome—a rare recessive autosomal disorder characterized by mild facial anomalies, cognitive impairment, recurrent infections, and lack of memory B-cells in peripheral blood (20–22). DNMT3B likely plays a role in pathogenesis of various hematologic malignancies as genetic alterations were identified in cutaneous T-cell lymphomas (CTCLs) and B-cell lymphomas (BCLs) (23, 24). Various other modes can affect activity of DNMT3B in cells. For instance, along with...
DNMT3A, DNMT3B belongs to the top 1% of underexpressed genes in human chronic lymphocytic leukemia (CLL) (25–27). Dnmt3b activity is also modulated by complexing with other proteins. For instance, a protein TCL1 that is overexpressed in a number of human T-cell malignancies, including mature leukemias, T-cell prolymphocytic leukemia, and B-cell malignancies, such as Burkitt's lymphoma and CLL (28, 29), binds to Dnmt3a and Dnmt3b and inhibits their activities (30) raising a possibility that Dnm3b activity is functionally decreased in a large number of hematologic malignancies. Studies in mice showed that Dnmt3b is a tumor suppressor (TS) in an oncogene-induced hematologic malignancies including T- and B-cell lymphomas induced by MYC and acute myeloid leukemia induced by MLL-AF9 (26, 31–34). Others reported oncogenic functions for Dnmt3b in MYC-induced T-cell acute lymphoblastic leukemia (T-ALL) likely due to its role in tumor maintenance (35).

Here we utilized genetic approaches to understand whether modulation of Dnmt3b activities in vivo by either decreasing gene dose using germline inactivation of one allele (Dnmt3b+/−) or decreasing or elimination of its CA through the use of recently generated catalytically inactive Dnmt3b CI allele (Dnmt3bCI/CI and Dnmt3bCI/C). Similarly to our previous study of Dnmt3a−/− mice, our data identify Dnmt3b as a haploinsufficient tumor suppressor in T-cell lymphomas (TCL) and CLL (36). We further found that several hypomethylated and overexpressed oncogenes including Jdp2, Trip13, and Stat1 may contribute to TCL along with downregulation of p53. A development of TCL was suppressed in Dnmt3bCI/CI and Dnmt3bCI/C suggesting that CA is less important for their development. Rather, a reduction in AF may be responsible for TCL development. This is further supported by methylation data from MYC-induced T-cell lymphomas with modulated Dnmt3b activities in which AF seemed to substantially suppress loss of methylation. In contrast, the observed development of CLL and BCLs in these mice suggest the importance in prevention of B-cell transformation. Furthermore, we found that CA is largely dispensable for postnatal development with mice surviving but developing ICF-like syndrome. In summary, our data show that Dnmt3b is a multifunctional protein involved in control of genes important to prevent ICF and tumorigenesis.

Results
Dnmt3b+/- mice develop T-cell lymphomas
To evaluate the long-term consequences of Dnmt3b haploinsufficiency in mice, we generated and observed cohorts of Dnmt3b+/− and Dnmt3b+/- mice for 18 months. While control Dnmt3b+/− and subset of Dnmt3b−/− mice remained healthy, with no signs of deregulated hematopoiesis, 44% of Dnmt3b−/− mice developed various hematologic malignancies including TCL, (20%) characterized by enlarged spleens and lymph nodes (Fig. 1, A and B, S1 and not shown). Histological analysis of spleens showed a near-complete effacement of the red pulp by massively expanded white pulp (Fig. 1C). Small-to medium-sized cells were present in both spleen and lymph nodes, and expressed markers of mature T-cells–CD3, CD5, TCRβ, and CD8 were negative for the expression of CD4, TCRγδ, NK-1.1, and CD16 (Fig. 1, C and D and not shown). In one case, we also observed a development of CD4+CD8+ immature TCL suggesting that decreased Dnmt3b levels may promote transformation of T-cells at earlier stages of the development (Figs. 1D and S1).

Dnmt3b+/− lymphomas were likely monoclonal because most T-cells in the tumor uniformly expressed the same TCR receptor, e.g., TCR-β 5.1 to 5.2 in tumor 1 or TCR-β 7 in tumor 2 (Fig. 1E). Cells showed full tumorigenic potential as transplantation of Dnmt3a−/− lymphoma cells induced peripheral T-cell lymphoma (PTCL) within 2 months in sublethally irradiated wild-type FVB recipient mice and while the same effect could be also observed upon subsequent transplantation of cells from tumors developed in recipient mice (Fig. 1, F and G). Tumors retained expression of Dnmt3b from wild-type allele suggesting that decreased levels of Dnmt3b, but not a complete inactivation, are sufficient to drive the disease development (Figs. 1H and S2). While Dnmt1 protein was downregulated, Dnmt3a level was increased in Dnmt3b+/− TCL possibly reflecting functional compensation for decreased Dnmt1/3b levels (Fig. 1H).

Altogether, these data demonstrate that the long-term Dnmt3b heterozygosity results in development of mostly mature CD8-positive TCLs similar to human PTCL—not otherwise specified (PTCL-NOS).

A subset of Dnmt3b+/- mice develop chronic lymphocytic leukemia
The second most common disease observed in Dnmt3b+/− cohort was a CLL-like disease observed in three mice and characterized by splenomegaly and CD5+B220+CD19+ B-1a cells expansion of more than 20% in the blood, spleen, and bone marrow (Figs. 1A, 2, A–C, S1 and data not shown). Three mice showed signs of monoclonal B-cell lymphocytosis (MBL)—a less progressed form of CLL—in which the percentage of B-1a cells (CD5+B220+CD19+) in the blood is between 2% and 20%, with simultaneous expansion in the spleen and bone marrow (Fig. 2C and data not shown). Importantly, splenic cells from mice with either MBL or CLL were able to induce disease in recipient mice (Fig. 2, D and E), demonstrating that both populations contain true leukemic cells. Therefore, we refer to both conditions as CLL-like disease. In addition to PTCL and CLL, we also observed the development of a myeloproliferative disease (MPD) in one of the Dnmt3b+/− mice (Figs. 1A, S1 and data not shown). These mice showed expansion of Gr-1+CD11b+ myeloid cells in the blood, spleen, and bone marrow (data not shown). Thus, our data identify Dnmt3b as a haploinsufficient tumor suppressor gene in the prevention of TCLs and CLL that also may play a role in prevention of myeloid malignancies in mice.

Dnmt3bCI CI mice survive postnatal development but develop ICF-like syndrome
Gene knockout of one allele in Dnmt3b−/− mice decreases all functions of Dnmt3b protein including CA, AF, and
methylation-independent repressive functions, thus precluding us to appreciate individual activities in in vivo. To determine the extent to which Dnmt3b CA plays a role in hematopoiesis and in its TS functions, we next utilized allele expressing catalytically inactive Dnmt3b (Dnmt3bCI) from endogenous locus. Dnmt3BWT and Dnmt3bCI protein levels are similar in mouse embryo and adult tissues demonstrating that an amino acid substitutions did not adversely affect regulation of Dnmt3b expression or protein stability as we reported previously (17).

Unlike Dnmt3b−/− mice, Dnmt3bCI/CI mice survived embryogenesis, but the importance of Dnmt3b CA in adult mice remains unclear (17). As a prelude to assessing its role in hematopoiesis, we first analyzed postnatal development in

---

**Figure 1. Majority of Dnmt3b+/- mice develop T-cell lymphomas.** A, Disease spectrum observed in Dnmt3b+/− mice (n = 35) determined by FACS. Values present percentage of mice diagnosed with indicated disease. B, Representative image of healthy spleen of Dnmt3b+/- (+/+ mice) and spleen and lymph node of terminal ill Dnmt3b+/- (+/−) mice that developed TCL. C, Histological staining of spleen and lymph node of age-matched Dnmt3b+/- control (+/+ and terminal ill Dnmt3b+/- mouse (+/− TCL) (magnification 40x). D, Representative FACS diagrams of CD4 and CD8 expression in cells isolated from the spleen of healthy Dnmt3b+/- (+/+) and terminal ill Dnmt3b+/- mice that developed CD8+ (+/− TCL1) and CD4+CD8+ (+/− TCL2) lymphomas. Quadrant statistics are indicated in red here and in all figures. E, Representative FACS diagrams showing clonal TCR-β expression in Dnmt3b+/- lymphomas (+/− tumor 1 and 2). F, Representative FACS diagrams of CD4 and CD8 expression in cells isolated from tumors that developed in terminal ill Dnmt3b+/- mice (primary tumor) and sublethally irradiated FVB-recipient mice injected with primary lymphoma (primary recipient). G, Time to tumor development for primary mice (primary TCL), primary (first) and secondary (second) sublethally irradiated FVB-recipient mice serially transplanted with primary TCL isolated from the lymph nodes of terminally sick Dnmt3b+/- mice. Data are presented as average time to tumor development. Two TCL lines are shown. H, Immunoblot analysis of Dnmt1, Dnmt3a, and Dnmt3b protein levels in healthy lymph node (C). Dnmt3bCI/CI (Δ/Δ) lymphomas. Hsc70 served as a loading control.
cohorts of Dnmt3b+/CI and Dnmt3bCI/CI mice. Dnmt3b+/CI mice were indistinguishable from their wild-type littermates and lived long lives. Dnmt3bCI/CI mice were relatively normal, but their body weight was ~20% lower than wild-type littermates at weaning, and this difference persisted throughout their postnatal lives (Fig. 3, A and B). Despite decreased size, both Dnmt3bCI/CI males and females had normal life span and were fertile with litter size similar to controls (Fig. 3C). However, inguinal fat was significantly reduced with smaller white adipose tissue (WAT) deposits in Dnmt3bCI/CI mice compared with controls (Fig. 3, D and E). Additionally, inguinal WAT showed presence of multilocular, brown-like adipocytes suggesting that Dnmt3b’s CA plays a role in regulation of their development (Fig. 3, F and G). Previously, a development of brown adipocytes was linked to hypomethylation of genes responsible for mitochondrial respiratory chain and fatty acid oxidation (37). Because insulin-like growth factor 1 (Igf1) is implicated in a regulation of fat deposition and body size (38), we next analyzed its expression in liver—a major organ for its production - of Dnmt3bCI/CI mice and found a small but significant reduction in transcript levels (Fig. 3H). Cerebral hyperplasia was also observed in Dnmt3bCI/CI mice, but the molecular mechanism behind this remains unclear (Fig. S3A). Dnmt3bCI/CI also had craniofacial defects including shortened nose, which is typical of ICF syndrome observed in humans and linked to DNMT3B mutations.
Figure 3. Loss of Dnmt3b’s CA results in postnatal growth retardation and ICF-like phenotype. A, Representative image of 6-week-old Dnmt3b<sup>+/+</sup> (+/+) and Dnmt3b<sup>CI/CI</sup> (CI/CI) mice. B, The weights of Dnmt3b<sup>+/+</sup> (+/+) and Dnmt3b<sup>CI/CI</sup> (CI/CI) mice measured at 1, 7, and 14 months (n = 10, each). Data are presented as mean ± SEM, *p < 0.001 (by two-tailed Student’s t-test). C, Fertility rates of Dnmt3b<sup>CI/CI</sup> (CI/CI) males and females showing observed and expected offspring genotypes, number of examined pairs of indicated genotypes, and average litter size are presented as mean ± STDEV. Differences are not statistically significant (χ<sup>2</sup> test) for genotype occurrence and two-tailed Student’s t-test for litter size. D, Representative image of inguinal white adipose tissue (WAT) isolated from Dnmt3b<sup>+/+</sup> (+/+) and Dnmt3b<sup>CI/CI</sup> (CI/CI) mice. E, Weights of inguinal WAT isolated from Dnmt3b<sup>+/+</sup> (+/+) and Dnmt3b<sup>CI/CI</sup> (CI/CI) mice normalized to body weight (n = 7, each). E, F, Representative image of inguinal WAT isolated from 8-week-old Dnmt3b<sup>+/+</sup> (+/+) and Dnmt3b<sup>CI/CI</sup> (CI/CI) mice at 20- and 200-fold magnifications. Arrows are pointing on brown-like adipocytes. G, Percentage of white and brown adipocytes in inguinal WAT of adult (8 weeks old) Dnmt3b<sup>+/+</sup> (+/+) and Dnmt3b<sup>CI/CI</sup> (CI/CI) mice. H, Real-time qRT-PCR analysis of Igf1 levels in the liver of adult Dnmt3b<sup>+/+</sup> (+/+) and Dnmt3b<sup>CI/CI</sup> (CI/CI) mice (n = 3, each), normalized to β-actin. I, Representative FACs diagrams showing CD19 and B220 expression in cells isolated from spleen of healthy (8 weeks old) Dnmt3b<sup>+/+</sup> (+/+) and Dnmt3b<sup>CI/CI</sup> (CI/CI) mice. Quadrant statistics are indicated in red. J, Absolute cell counts of B-cells (CD19 + B220+), myeloid cells (CD11b+CD5-), and mature T-cells (CD4+CD3+ and CD8+CD3+) in the spleen of Dnmt3b<sup>+/+</sup> (+/+) and Dnmt3b<sup>CI/CI</sup> (CI/CI) mice (n = 6) as analyzed by FACs. Data are presented as mean ± SEM, *p < 0.02 by two-tailed Student’s t-test.

(Fig. S3, B and C). Consistently with the syndrome, hematopoiesis was less efficient with mildly decreased production of CD11b+ myeloid, CD3+ T-cells, and especially CD19+ B220+ B-cells observed in the spleens of Dnmt3b<sup>CI/CI</sup> mice (Figs. 3, I and J and S4).

Altogether, our data show that Dnmt3b’s CA is dispensable for postnatal development and fertility, but its absence results in a decreased body weight at least partially due to a fat deposition decrease likely associated with reduced Igf1 production in Dnmt3b<sup>CI/CI</sup> mice. Loss of Dnmt3b’s CA induces phenotypes consistent with ICF syndrome in humans, in particular craniofacial defects and less efficient adult hematopoiesis.

**Dnmt3b’s CA is important for its tumor suppressor function in spontaneous lymphomagenesis**

To determine if Dnmt3b’s CA is important for its TS function in mouse spontaneous lymphomagenesis, we compared survival in cohorts of Dnmt3b<sup>+/+</sup>, Dnmt3b<sup>V/C</sup>, and Dnmt3b<sup>CI/CI</sup> mice. Similar to Dnmt3b<sup>+/+</sup>, Dnmt3b<sup>V/C</sup> mice developed a spectrum of hematologic malignancies including
Compared with Dnmt3b+/− mice with 44%, a combined disease penetrance in Dnmt3b+/CI mice was reduced to 35% (23/67 mice) with 65% of mice remaining healthy during the observational period of 18 months. Importantly, the disease spectrum was substantially changed with MBL and CLL being

Figure 4. Dnmt3b’s CA is important in the prevention of hematologic malignancies. A, Disease spectrum of Dnmt3b+/+ (+/+; n = 30) Dnmt3b+/CI (+/CI; n = 67), and Dnmt3bCI/CI (CI/CI; n = 32) mice as determined by FACS. B, Representative image of the enlarged spleen of terminally ill Dnmt3b+/+ (+/+) mouse that developed CLL and healthy spleen of age-matched Dnmt3b+/+ (+/+). C, Representative FACS diagram of CD5 and CD19 expression in cells isolated from the spleen of healthy Dnmt3b+/+ mice (+/+ and CI/CI mice that developed MBL as analyzed by FACS. Quadrant statistics are indicated in red here and throughout whole figure. D, CD5, CD19, and B220 expression in cells isolated from the spleen of terminally sick Dnmt3b+/CI mice (+/CI) and healthy Dnmt3b+/+ mice (+/+) and terminally sick Dnmt3bCI/CI (CI/CI) mice that developed CLL as analyzed by FACS. E, Time to tumor development for primary mice (primary CLL), primary (first), secondary (second), and tertiary (third) sublethally irradiated FVB-recipient mice serially transplanted with cells isolated from the spleen of terminally sick Dnmt3b+/CI mouse. Data are presented as mean ± SEM. F, CD5 and CD19 expression in cells isolated from the spleen of healthy Dnmt3b+/+ mice (+/+) and terminally sick Dnmt3b+/CI mice (+/CI) that developed BCL as analyzed by FACS. Expression of IgM and IgD on CD19+CD5-cells is shown on the bottom panel.
the most frequent diseases observed in these mice 20% (13/67 mice) and 6% (4/67 mice), respectively (Figs. 4A and S5). MBL and CLL were characterized by enlarged spleen and expansion of CD5+CD19+ B220+ cells in the spleen and blood (Fig. 4, B–D and not shown) similar to Dnmt3b+/− mice. These cells induced disease in recipient mice upon serial transplantation into sublethally irradiated recipient mice demonstrating true leukemic nature (Fig. 4E). In addition, we also observed a development of immature BCL characterized by expansion of CD19+CD5-IgM-IgD-cells in the spleen (Fig. 4F).

TCL development was less frequent relative to Dnmt3b+/− mice with only 4% (3/67) of mice developing CD8+ TCL (Figs. 4A, S5 and S6). As observed in Dnmt3b+/− TCL, Dnmt3b+/−/− TCL tumors were serially transplantable into sublethally irradiated recipient mice demonstrating full tumorigenic transformation (not shown).

In total, 2/67 mice developed myeloproliferation characterized by expansion of CD11B-cells in the bone marrow (Fig. S7).

While the disease spectrum was similar in Dnmt3b+/−/CI/CI mice, the penetrance of leukemia/lymphoma development was decreased with 31% of observed mice developing MBL/CLL and TCL (Fig. 4A). In summary, these data suggest that CA contributes substantially to Dnmt3b’s TS function, in particular in B-cell malignancies.

**Methylocens of Dnmt3b+/− and Dnmt3aΔΔ lymphomas have both overlapping and unique features**

The development of TCL and CLL in Dnmt3b+/− mice resembles phenotypes observed in Dnmt3a+/− and Dnmt3aΔΔ mice raising a possibility that similar molecular events drive lymphomagenesis in these settings (26, 36, 39). To assess this, we next analyzed methylocens of Dnmt3b+/− and Dnmt3aΔΔ TCL and publicly available normal thymus (ENCODE, Joe Ecker, Salk lab, ENCSR001MFH (40)) by whole-genome bisulfite sequencing (WGBS). Initial analysis revealed that 6,300,000 CpG dinucleotides were covered at least 5x in all tested samples (Figs. S8 and S9). Out of these, 267,542 (4.2%) differentially methylated cytosines (DMCs; ≥30% change in methylation as analyzed by Metilene) showed ≥30% methylation reduction and 10,379 (0.16%) DMCs had ≥30% methylation increase in Dnmt3b+/− PTCL cells when compared with normal thymus (Figs. 5, A and B and S9). In Dnmt3aΔ−/− PTCL, we identified 441,135 (7%) DMCs hypomethylated and 18,572 (0.29%) DMCs hypermethylated when compared with a normal control (Figs. 5B and S9). Interestingly, 166,047 (~62%) hypermethylated DMCs were overlapping between Dnmt3b+/− PTCL and Dnmt3aΔ−/− PTCL (Fig. 5B). Hypomethylation in both tumor groups was apparent for many genomic features including long and core promoters, exons, introns, CpG islands, and repeat elements (Figs. S10 and S11). Further analysis revealed 4433 hypomethylated and 548 hypermethylated differentially methylated regions (DMRs; ≥3 consecutive DMCs in the distance ≤50 bp with methylation change in the same direction ≥30%, p (MWU) < 0.05 as analyzed by Metilene) in Dnmt3b+/− PTCL (Fig. 5C). Of these, 2314 hypomethylated and 168 hypermethylated DMRs were identified also in Dnmt3aΔ−/Δ PTCL, and the overlap was observed across the genome (Fig. 5, C–E). Based on methylation patterns, Dnmt3b+/− and Dnmt3aΔ−/Δ PTCL clustered closer and apart from normal thymus control (Fig. S12). This similarity is likely driven by decreased Dnmt3b and Dnmt3a levels. It does not seem to be just a consequence of T-cell transformation due to overlaps in hypomethylated DMRs being detected between Dnmt3b+/− and Dnmt3aΔ−/Δ PTCL, especially in introns and repeats, even after hypomethylated DMRs present in wild-type MYC-induced TCLs expressing Dnmt3a and Dnmt3b were filtered out (Figs. S13 and S14). Such results suggest that Dnmt3b and Dnmt3a may cooperate in regulating target loci methylation. Data obtained from WGBS were further validated by combined bisulfite restriction analysis (COBRA), which showed DMRs substantially hypomethylated in promoters of Il2Rβ, Coro2a, and Ptt1 genes in Dnmt3aΔ−/− TCL (Fig. 5F). Interestingly, these loci were even more hypomethylated in Dnmt3bΔ−/Δ, Dnmt3aΔ−/−, and Dnmt3aΔΔ lymphomas we derived in our previous studies (26, 31, 39) further suggesting interplay between Dnmt3b and Dnmt3a in their methylation functions (Fig. 5F). Thus, our analysis of methylocens identifies both specific and overlapping events associated with decreased Dnmt3b and Dnmt3a levels in mouse lymphomas.

**Putative overlapping targets of Dnmt3b and Dnmt3a are associated with H3K4me1 and H3K27ac marks**

Our analysis revealed 2314 DMRs hypomethylated in both Dnmt3b+/− PTCL and Dnmt3aΔ−/Δ PTCL raising a possibility that methylation of these regions depends on activity of both Dnmt3b and Dnmt3a (Fig. 5C). We term these DMRs as 3a/b-overlapping, such as Lclk4 and Dhrs3 loci (Fig. 6A). In total, 2119 DMRs were specifically hypomethylated only in Dnmt3b+/− PTCL (3b-specific) (Fig. 5C), for instance, Trflocus and Hist2h3b promoter (Fig. 6B). In total, 5287 hypomethylated DMRs were detected specifically only in Dnmt3aΔ−/Δ PTCL (3a-specific), e.g., Ahdc1 and 1110020A21Rik loci (Figs. 5C and 6C). To analyze association between histone modifications and these three types of DMRs, we next utilized available ChiP-seq data of normal Dnmt3b+/− thyromyces (ENCODE-ENCSR325LOF) (40). We found that 3a-specific and 3a/3b-overlapping DMRs are marked with H3K4me1, H3K27ac, and H3K36me3 on a genome-wide level in normal thymus (Fig. 6D). This signature was present in various genomic regions including enhancers, promoters, introns, exons, and repetitive elements (Fig. S15). In contrast, we did not observe any specific chromatin signature genome-wide or in individual genomic elements in 3b-specific DMRs in normal thymus (Figs. 6D and S15). To determine the effects of DNA methylation, we next analyzed association between promoter hypomethylation and gene expression in Dnmt3b+/− PTCL and found that 13/126 3b-specific hypomethylated promoters (10%) had increased expression relative to thymic control (termed G1 group; FC ≥ 2, p < 0.05; Fig. 6E and Supporting Information 1). Genes unchanged in expression upon
promoter demethylation belonged to two distinct groups characterized by either high (G2 group; FPKM>0.2; n = 77) or low (G3 group; FPKM<0.2; n = 36) FPKM values in normal thymus (Fig. 6E and Supporting Information 1). G1 genes were expressed in thymus, had open chromatin around transcription start site (TSS) and enrichment in both activating H3K4me3 and H3K27me3 repressive histone marks (Fig. 6, E and F and Supporting Information 1). G2 genes were already expressed in control thymus, had open chromatin and only activating histone marks around TSS (Fig. 6, E and F and Supporting Information 1). G3 genes were not expressed in thymus, had closed chromatin and enrichment in repressive H3K27me3 mark around TSS (Fig. 6, E and F and Supporting Information 1). Thus, DNA methylation appears to provide additional layer of regulation for genes with histone mark signature H3K4me3+H3K27me3+ that is characteristic for bivalent promoters, whereas it seems to be less important for genes with repressive H3K27me3+ mark only or for the actively transcribed genes.

### Tumor suppressor p53 and putative oncogenes are deregulated in Dnmt3b⁻/⁻ lymphomas

To understand further molecular effects of monoallelic Dnmt3b loss on TCL development and the extent to which it resembles Dnmt3a-deficient lymphomas, we next analyzed gene expression in Dnmt3b⁻/⁻ and Dnmt3a⁻/Δ TCLs by RNA-seq.
In total, 2076 upregulated and 1018 downregulated genes (FC ≥ 2, p < 0.05) were identified in Dnmt3bΔ−/Δ TCL relative to normal control (Fig. 7A and Supporting Information 2). Out of these, 939 upregulated and 510 downregulated events were shared between both types of lymphomas with remaining changes specific to Dnmt3b and additional specific ones found in Dnmt3aΔ/Δ TCL (Fig. 7A and Supporting Information 2). Thus, ~40% deregulated genes are shared between both groups suggesting that these lymphomas may have common drivers of disease development (Fig. 7A and Supporting Information 2). Based on their expression profiles, Dnmt3bΔ−/− and Dnmt3aΔ/Δ TCL clustered together and apart from normal CD8+ T-cells (Fig. S16).
Ingenuity pathway analysis (IPA) using 3a/b shared gene expression changes (Fig. 7A and Supporting Information 2) revealed upregulated interferon signaling, estrogen-mediated S-phase entry, cyclins and cell cycle regulation and suppression of G2/M DNA damage regulation, p53 signaling, and cell cycle G1/S regulation (Fig. 7B). P53 pathway downregulation was also identified by gene set enrichment analysis (GSEA) (Fig. 7C). The importance of p53 in prevention of T-cell transformation in mice (41) prompted us to examine the p53 protein during lymphomagenesis in Dnmt3b+/− mice. P53 levels in thymi of symptomless Dnmt3b+/− mice at different ages were unaffected relative to control Dnmt3b+/+ (Fig. 7D). In contrast, p53 was

![Figure 7. P53 pathway is commonly deregulated in Dnmt3b+/− and Dnmt3aΔ/Δ TCL. A, Heat map showing fold change expression values of subset of differentially expressed genes (FC ≥ 3, p < 0.05 by DESeq) in Dnmt3b+/− (3b+/−; n = 3) and Dnmt3aΔ/Δ (3aΔ/Δ; n = 3) lymphomas when compared with control CD8+ T-cells (CD8; n = 2). B, Ingenuity pathway analysis of genes commonly deregulated (FC ≥ 3, p < 0.05 by DESeq) in Dnmt3b+/− and Dnmt3aΔ/Δ lymphomas when compared with control CD8+ T-cells. The top canonical pathways are displayed (p < 0.05 by right-tailed Fisher’s exact test). C, GSEA using RNA-seq data shows negative enrichment in P53 pathway in Dnmt3b+/− (3b+/−) and Dnmt3aΔ/Δ (3aΔ/Δ) lymphomas when compared with control CD8+ T-cells. Normalized enrichment scores (NES), false discovery rate (FDR), and p-values are shown. D, Immunoblot analysis of p53 protein levels in healthy 8 weeks and 8-month-old wild-type (+/+ and Dnmt3b+/− (+/−) mice and Dnmt3b+/− lymphomas (tumors). Hsc70 served as a loading control. E, Jdp2 expression by RNA-seq in control CD8+ T-cells (CD8; n = 2) and Dnmt3b+/− (3b+/−; n = 3) lymphomas. F, Heat maps showing overlap between promoter hypomethylation (meth. diff. ≥30%; p(MWU) <0.05) and gene overexpression (FC ≥ 2, p < 0.05 by DESeq) in Dnmt3b+/− (n = 3) and Dnmt3aΔ/Δ (n = 3) lymphomas when compared with control CD8+ T-cells (C; n = 2). G, Trip13 expression by RNA-seq in control CD8+ T-cells (CD8; n = 2) and Dnmt3b+/− (3b+/−; n = 3) lymphomas. H, Stat1 expression by RNA-seq in control CD8+ T-cells (CD8; n = 2) and Dnmt3b+/− (3b+/−; n = 3) lymphomas. I, Percentage of methylation at individual CpGs of Stat1 promoter locus in Dnmt3b+/− (3b+/−) and Dnmt3aΔ/Δ (3aΔ/Δ) lymphomas and in healthy thymus (+/+).

EDITORS’ PICK: Dnmt3b’s haploinsufficiency drives lymphomagenesis
downregulated in Dnmt3b<sup>V−/−</sup> TCL consistently with downregulation detected by IPA and GSEA highlighting its likely involvement in tumorigenesis (Fig. 7D). Trp53 transcript levels were not downregulated in lymphomas (data not shown) suggesting rather a proteolytic degradation. A major negative regulator of p53—Mdm2—was not upregulated indicating no involvement in its proteolytic degradation (Fig. S17).

We have recently linked a negative regulator of Trp53—Jun dimerization protein 2 (Jdp2) as a contributor to p53 downregulation in Dnmt3a<sup>Δ/Δ</sup> TCLs (39, 42). Interestingly, analysis of RNAseq data identified upregulation of Jdp2 suggesting that its increased expression may contribute to p53 downregulation also in Dnmt3b<sup>V−/−</sup> TCL (Fig. 7E). Because Dnmt3b hypomethylinsufficiency resulted in TCL with substantially deregulated methylomes, we next hypothesized that gene hypomethylation accompanied by increased expression may also contribute to lymphomagenesis (Fig. 7F and Supporting Information 3). We identified 22 genes that become overexpressed upon promoter hypomethylation in Dnmt3b<sup>V−/−</sup> TCL. Out of these, nine genes were also hypomethylated and overexpressed in Dnmt3a<sup>Δ/Δ</sup> TCLs suggesting that these are shared targets of Dnmt3b and Dnmt3a. This signature contained several genes with possible oncogenic activities in TCL including Trip13 and Stat1 (43, 44). Both were strongly upregulated and hypomethylated in all Dnmt3b<sup>V−/−</sup> TCL (Fig. 7, G–I and S18).

Stat1 activation was also detected by Panther and Reactome pathway analysis using hypomethylated and overexpressed genes through deregulation of IL9 and IL21 signaling (Fig. S19). Given the well-established role of Stat1 as an oncogene in T-cells, our data strongly suggest that this upregulation contributes to lymphomagenesis (44).

Altogether, these data suggest that downregulation of p53 and upregulation of Jdp2 and Stat1 are likely relevant in initiation/progression of lymphomagenesis.

**Dnmt3b’s CA and AF contribute to generation of TCLs methylomes**

Because TCL development observed in Dnmt3b<sup>V−/−</sup> mice was suppressed in Dnmt3b<sup>CI/CI</sup>, we were unable to analyze molecular effects of Dnmt3b’s CA on the tumor methylome. We, therefore, sought to use a model allowing us to compare TCLs methylomes obtained from full Dnmt3b inactivation to those without Dnmt3b’s CA. Therefore, we used EμSra-tTA;Teto-MYC model in which MYC transgene overexpression results in a development of immature TCLs (45). We have previously shown that a conditional loss of Dnmt3b in EμSra-tTA;Teto-MYC;Teto-Cre;Rosa26LOXF<sup>GFP</sup>;Dnmt3b<sup>fl/fl</sup> mice (termed MYC;Dnmt3b<sup>V−/−</sup>CA) resulted in accelerated TCL (31). Here we generated EμSra-tTA;Teto-MYC;Dnmt3b<sup>CI/CI</sup> mice (termed MYC;Dnmt3b<sup>CI/CI</sup>) and observed that mice and harvested CD4+CD8+ TCLs that developed in these mice (Fig. S20). Next, we used WGBS to determine methylation patterns in MYC;Dnmt3b<sup>CI/CI</sup>, MYC;Dnmt3b<sup>CI/CI</sup>, and MYC;Dnmt3b<sup>Δ/Δ</sup> lymphomas (31) (two samples per genetic group). WGBS data were next compared with methylation data derived from Dnmt3b<sup>V−/−</sup> TCL (Fig. 5) and normal thymus (ENCSR001MFH) (40) (Figs. S8 and S21). This comparison yielded methylation readouts of 5,499,675 CpGs covered ≥5% in all samples. All lymphomas showed reduction in methylation relative to thymocytes with the highest percentage of hypomethylated DMCs (≥30% change in methylation as analyzed by Metilene based on average of two samples) present in MYC;Dnmt3b<sup>Δ/Δ</sup> lymphomas (21.1%) and the lowest in Dnmt3b<sup>V−/−</sup> TCL (9.6%) (Fig. 8, A and B). Gains in methylation were also seen affecting approximately 0.4% of CpGs in all lymphomas (Fig. 8A). DMR analysis (DMR defined as ≥3 consecutive DMCs in the distance ≤50 bp with methylation change in the same direction ≥30%, p (MWU) <0.05 as analyzed by Metilene based on average of two samples) revealed that MYC;Dnmt3b<sup>Δ/Δ</sup> TCLs had the highest number of hypomethylated and the lowest number of hypermethylated DMRs relative to normal thymocytes (~27,000, and ~1,100, respectively; Fig. 8C). Total number of hypomethylated DMRs was similar between MYC;Dnmt3b<sup>V−/−</sup> and MYC;Dnmt3b<sup>CI/CI</sup> lymphomas (~23,000) suggesting that Dnmt3b<sup>CI</sup> protein restored at least some Dnmt3b functions lost in MYC;Dnmt3b<sup>Δ/Δ</sup> lymphomas (Fig. 8C). The lowest number of hypomethylated DMRs was observed in Dnmt3b<sup>V−/−</sup> TCL (Fig. 8C). A number of hypermethylated DMRs was similar ~2000—across all tumor groups.

To begin to uncover putative targets of Dnmt3b’s CA or AF, we first filtered out ~3500 mostly hypomethylated DMRs that were observed in all MTCLs presumably as a result of transformation and thus not linked to Dnmt3b (data not shown). As many as 9702 hypomethylated DMRs were present only in MYC;Dnmt3b<sup>CI/CI</sup> or MYC;Dnmt3b<sup>Δ/Δ</sup> suggesting that these DMRs may represent putative targets of Dnmt3b’s AF (Fig. 8D). Thus, Dnmt3b<sup>CI</sup> may have contributed to retaining of methylation of ~80% of regions (9702/12,189) that are hypomethylated in MYC;Dnmt3b<sup>Δ/Δ</sup> TCL. In contrast, 2487 DMRs may represent putative targets of Dnmt3b’s CA because they were detected in both MYC;Dnmt3b<sup>Δ/Δ</sup> and MYC;Dnmt3b<sup>CI/CI</sup> MTCLs (Fig. 8D). Further analysis revealed 1335 hypermethylated DMRs out of which 322 were present in MYC;Dnmt3b<sup>V−/−</sup>, MYC;Dnmt3b<sup>Δ/Δ</sup>, and MYC;Dnmt3b<sup>CI/CI</sup> TCL and therefore likely not dependent on Dnmt3b activities (Fig. 8D and data not shown), while 479 might be putative targets of Dnmt3b’s AF because they were detected in MYC;Dnmt3b<sup>CI/CI</sup> but not in MYC;Dnmt3b<sup>Δ/Δ</sup> TCL. In addition, 524 DMRs might be putative targets of Dnmt3b’s CA because they are hypermethylated in MYC;Dnmt3b<sup>V−/−</sup> lymphomas but not in MYC;Dnmt3b<sup>Δ/Δ</sup> or MYC;Dnmt3b<sup>CI/CI</sup> MTCLs that lack CA (Fig. 8D).

A small subset of a putative targets of Dnmt3b’s AF and CA in MTCL lymphomas (both hypo- and hypermethylated) was also observed in Dnmt3b<sup>V−/−</sup> TCL suggesting that these loci might be in particular sensitive to decreased levels of Dnmt3b (Fig. 8E).

Dnmt3b’s targets in TCLs were distributed relatively equally across various genomic elements including promoters, gene bodies, enhancers, and repeats, but AF appears to be more involved in preventing hypomethylation in gene bodies (Figs. 8F and S22). In contrast, a relative contribution of CA to hypermethylated DMRs seems to be increased in promoters possibly indicating a direct role in de novo methylation (Figs. 8F and S22).
Altogether, our data indicate that Dnmt3b’s AF plays a major role in lymphomagenesis substantially suppressing loss of methylation observed in tumors without Dnmt3b perhaps because it may be involved in maintenance methylation. Furthermore, both CA and AF may be important in a generation of hypermethylated DMRs possibly indicating a role in de novo methylation. However, such conclusions have to be further confirmed in more functional studies in the future.

Discussion

Here we show that decreasing Dnmt3b’s activities in vivo in Dnmt3b<sup>+/−</sup>, Dnmt3b<sup>+/−CI</sup>, and Dnmt3b<sup>CI/CI</sup> mice results in development of various hematologic malignancies, mostly TCL and CLL, highlighting its tumor suppressor function in spontaneous lymphomagenesis.

Several interesting results were obtained from phenotypic observations in mice. For instance, mice expressing Dnmt3b<sup>CI</sup> developed hematologic malignancies with decreased incidence relative to Dnmt3b<sup>+/−</sup> mice. This could be due to a different magnitude of DNA methyles deregulation in Dnmt3b<sup>+/−CI</sup> and Dnmt3b<sup>CI/CI</sup> lymphomas, which is likely less pronounced than in Dnmt3b<sup>+/−</sup> lymphomas. This hypothesis stems from the fact that Dnmt3b<sup>CI</sup> protein retains AF consisting of the ability to recruit other DNMTs, which provide their CA for cytosine

Figure 8. A comparison of methylomes derived from Dnmt3b<sup>ΔΔ</sup>, Dnmt3b<sup>CI/CI</sup>, and Dnmt3b<sup>Δ/+</sup> T-cell lymphomas. A, Left. Total numbers of DMCs (meth. diff. ≥30%) as based on average of two samples; covered ≤5x in MYC;Dnmt3b<sup>Δ/+</sup>, MYC;Dnmt3b<sup>Δ/Δ</sup> (ΔΔ), MYC;Dnmt3b<sup>CI/CI</sup> (CI/CI), and Dnmt3b<sup>Δ/+</sup> (Δ/+). B, Comparison of average differences between methylation levels of corresponding CpGs of healthy thymus and MYC;Dnmt3b<sup>Δ/+</sup>, MYC;Dnmt3b<sup>Δ/Δ</sup>, MYC;Dnmt3b<sup>CI/CI</sup>, and Dnmt3b<sup>Δ/+</sup> lymphomas (n = 2 each). Data are presented as mean ±SEM. C, Total number of hypo- and hypermethylated DMRs (≥3 consecutive DMCs in the distance ≤50 bp with methylation change in the same direction ≥30%, p (MWU) < 0.05 as analyzed by Metilene based on average of two samples) identified in lymphomas of indicated genotypes (n = 2 each). D, Heat map showing DMRs identified in MYC;Dnmt3b<sup>Δ/+</sup>, MYC;Dnmt3b<sup>Δ/Δ</sup>, MYC;Dnmt3b<sup>CI/CI</sup>, and Dnmt3b<sup>Δ/+</sup> lymphomas relative to normal thymocytes (n = 2 each). E, Number of hypermethylated and hypermethylated DMRs identified in Dnmt3b<sup>Δ/+</sup> lymphoma and their overlap with putative targets of Dnmt3b’s catalytic and accessory functions are indicated. F, Number of hypo- and hypermethylated DMRs identified in lymphomas of indicated genotypes (n = 2 each) and MYC-induced lymphomas analyzed in (D) are indicated by stripped bars. Overlapping is indicated by striped bars and labeled overlapping.
methylated thereby stabilizing methylene. Such AF rescued 95% of DNA methylation during mouse embryogenesis in Dnmt3bΔ/Δ embryos at E11.5 (17). Alternatively, accumulation of other pathogenic events such as deregulated gene expression or genetic alterations is favored in Dnmt3bΔ/Δ mice. Regardless of the reason for a decreased disease penetrance in Dnmt3bΔ/Δ and Dnmt3bΔ/Δ mice, our data clearly demonstrate that even monoallelic inactivation of Dnmt3b’s CA activity promotes malignant hematopoiesis highlighting its crucial role—and in a broader sense the role of reduced cytosine methylation—in the prevention of hematopoietic cell transformation.

Another interesting finding is that Dnmt3bΔ/Δ mice had decreased tumor incidence relative to Dnmt3bΔ/Δ (from 35% to 31%) and changed disease spectrum, which is surprising as full CA inactivation would be predicted to promote, rather than suppress, tumorigenesis. However, this could be caused by hematopoietic cell reduction resulting in a smaller cellular pool available for transformation or changes in microenvironment due to the presence of homozygous germline Dnmt3b inactivation of CA in Dnmt3bΔ/Δ mice. Interestingly, data obtained here on mice with different Dnmt3b activities are similar to those observed in mice with varying degrees of Dnmt3a inactivation. A conditional inactivation of Dnmt3a in hematopoietic cells results in 100% disease penetrance predominantly CLL with few cases of PTCL. Similarly, Dnmt3aΔ/Δ mice harboring a conventional knockout allele of Dnmt3a in FVB mouse strain develop either MBL/CLL or PTCL or MPD with 67% penetrance over 16 months (39). Dnmt3aΔ/Δ mice on BL6 background developed various myeloid conditions including myeloproliferative disease and myeloid leukemia with 56% penetrance over the course of 2 years (46). Taken all these data together, a decrease in Dnmt3b favors development of T-cell malignancies, while the CA seems less important due to the disease being less penetrant in Dnmt3bΔ/Δ and Dnmt3bΔ/Δ compared with Dnmt3bΔ/Δ mice. In contrast, loss of only Dnmt3b’s CA but not AF in Dnmt3bΔ/Δ mice favors development of B-cell malignancies in particular CLL. Similarities in phenotypic consequences of long-term heterozygosity in mice suggest that Dnmt3a and Dnmt3b may coordinate control genes contributing to transformation. We identified several molecular events that are similar between Dnmt3bΔ/Δ and Dnmt3aΔ/Δ TCL. One important molecular event observed in Dnmt3bΔ/Δ TCL is downregulation of tumor suppressor p53 on protein level, which we also detected in Dnmt3aΔ/Δ TCL previously (39). Decreased p53 contributes to T-cell transformation as Trp53Δ/Δ mice are highly susceptible to spontaneous development of thymic lymphomas (41). Like in Dnmt3aΔ/Δ TCL, we also found that Jdp2—a component of the AP-1 transcription factor complex that represses transactivation-mediated by the Jun family of proteins—is upregulated in a majority of Dnmt3bΔ/Δ TCL. Jdp2 is an oncogene that collaborates with the loss of p27kip1 cyclin-dependent inhibitor to induce lymphomas (47) and also negatively regulates Trp53 promoting T-cell leukemia development in mice (42). Jdp2 upregulation in Dnmt3aΔ/Δ PTCLs was associated with decreased p53 and causatively contributed to disease progression (39). Similarly, Jdp2 is upregulated in majority of Dnmt3bΔ/Δ lymphomas while p53 is downregulated suggesting that similar to Dnmt3aΔ/Δ PTCLs, both events may be linked or contribute independently to lymphomagenesis. Additional putative oncogenic event shared between Dnmt3bΔ/Δ and Dnmt3aΔ/Δ PTCL was promoter hypomethylation accompanied by gene upregulation. Genes with oncogenic functions, such as Stat1 and Trip13, were upregulated possibly contributing to disease initiation/progression (43, 44, 48). Thus, downregulation of p53 along with activation of oncogenes likely represents important events promoting lymphomagenesis in both Dnmt3aΔ/Δ and Dnmt3aΔ/Δ mice.

Analysis of Dnmt3aΔ/Δ and Dnmt3aΔ/Δ TCL methylation and its association with histone marks also revealed that both Dnmt3a-specific and Dnmt3a/b-overlapping hypomethylated DMRs are associated with H3K4me1, H3K27ac, and H3K27me3 in normal thymus on a genome-wide level. In contrast, no specific chromatin modification signature on genome-wide level in Dnmt3b specific DMRs in normal thymus was found.

These data are in line with our previous study suggesting that in embryos, the accessory activity of Dnmt3b is promoted by the presence of activating marks such as H3K36me3 (17). The fact that we observe such association in thymus for Dnmt3a/b-overlapping but not Dnmt3b-specific DMRs suggests that Dnmt3a may be the enzyme providing CA, while Dnmt3b supplies AF function for the methylation of these loci. At the same time, CA of Dnmt3b was associated with the presence of repressive H3K27me3 in embryos, but not on genome-wide level in thymus. However, a group of 13 genes (G1 group), whose promoters were marked by both activating H3K4me3 and H3K27me3 repressive histone marks in normal thymocytes, was the only group of genes responding to promoter methylation loss by gene upregulation specifically in Dnmt3bΔ/Δ tumors. By the presence of H3K4me3 and H3K27me3 marks, G1 group resembles genes with bivalent promoters. Given previous reports that promoters that are marked with H3K27me3 in embryonic stem cells are more likely to gain DNA methylation during differentiation, and that DNA methylation promotes acquisition of H3K27me3 on bivalent promoters (2, 49), our data suggest that Dnmt3b-dependent DNA methylation contributes to regulation of expression at least in a subset of genes containing bivalent promoters.

Additional interesting findings came from a generation and methylome analysis of MYC-induced TCLs that either had full Dnmt3b inactivation MYC;Dnmt3bΔ/Δ or just inactivation of its CA while retaining other functions including accessory (MYC;Dnmt3bΔ/Δ). This analysis revealed that contribution of Dnmt3b’s AF to maintenance methylation may be higher than the CA itself because 80% of hypomethylated DMRs seen in MYC;Dnmt3bΔ/Δ were not seen in MYC;Dnmt3bΔ/Δ. In contrast, both CA and AF appear to be relatively equally contributing to the generation of hypermethylated DMRs in particular in promoters possibly highlighting their equivalent role in de novo methylation. However, these conclusions were
derived from differential analysis of mouse tumors in which numerous activities are deregulated providing a lot of variables that may affect data interpretation. Therefore, a caution has to be exercised in our data interpretation before more rigorous functional approaches confirm such conclusions. Nonetheless, our data point to involvement of Dnmt3b’s CA and AF in basic methylation functions in mouse lymphomagenesis.

Another interesting aspect of this study is finding that Dnmt3b’s CA is largely dispensable for postnatal development yet playing a role in fat metabolism and preventing development of ICF-like syndrome. Several features of Dnmt3bCI/CI mice are consistent with human ICF syndrome including facial anomaly, reduced body weight, and hematopoietic defects, especially impaired lymphocyte development. We identified additional feature associated with ICF syndrome—cerebral hyperplasia. This is not associated with higher sensitivity to malignant development as we have not detected brain tumors in any of the analyzed mice. Rather, this result points to a typical clinical observation of psychological and cognitive developmental delay in observed in ICF patients (50).

Attempts to establish ICF model were previously done by generation of mice expressing analogues of human DNMT3B single-point mutations derived from ICF patients such as A609T mutant, which disrupts the interactions with Dnmt3a and Dnmt3b1, and D823G, altering protein localization (51). While homozygous mutant mice were born and had ICF-like features, they were not viable with most mice dying within 24 h.

Dnmt3bCI/CI mice, like humans, survive postnatal development and resemble individuals with ICF, thus may serve as good models for understanding the etiology of ICF syndrome and identification of target genes regulated by DNA methylation during development.

Methods

Mouse studies

To generate conventional Dnmt3b knockout allele, we used the approach described previously (31, 36, 39) utilizing Dnmt3bloxPloxP mice obtained from E. Li (Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA). Mice were kept in FVB/N genetic background and were generated using standard genetic crosses. Mice harboring conventional knock-in mutations (P656 V and C657D) in Dnmt3b coding sequence (Dnmt3bCI) were generated as described before (17). EμSra-tTA;Teto-MYC mice were obtained from D.W. Felsher (Stanford University). Mice harboring conditional knockout of Dnmt3b (EμSra-tTA;Teto-MYC;TetoCre; Rosa26-loxpEFGP;Dnmt3bloxPloxP - termed MYC;Dnmt3bΔ/Δ) were generated as described before (31). For MYC-induced T-cell lymphomagenesis studies, EμSra-tTA;Teto-MYC;Dnmt3bCI/CI (termed MYC;Dnmt3bCI/CI) mice were harvested when terminally sick. Cells from lymphomas were analyzed by FACS, used for DNA isolation and WGBS. All experimental animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Florida under protocol number 201609589 and complied with all relevant ethical regulations for animal testing and research. All mice were housed in a pathogen-free barrier facility at the UF.

Histology

Formalin-fixed paraffin-embedded sections (4 μm) of the spleen, lymph node, and inguinal WAT were stained with hematoxylin (Sigma, H9627) for 40 s and with eosin (Sigma-Aldrich, HT110116) for 30 s. The tissue sections were mounted with Permament mounting medium (Fisher Scientific, SP15–100). All procedures were conducted by Molecular Pathology Core, University of Florida. Images were generated with a Zeiss Axio Imager 2 microscope (Carl Zeiss, Inc, Thornwood, NY). For adipose tissue analysis, adipocytes were counted for four nonoverlapping fields of view for three Dnmt3bCI/CI and Dnmt3bCI/CI mice. Cells with single large lipid droplet were considered white adipocytes and cells with multiple small droplets—brown.

Skeletal staining

For cranium staining, mice heads were skinned and macerated in 2% KOH for 3 days. Eviscerated skulls were stained with 0.005% Alizarin Red (Sigma-Aldrich, A5533) solution for 4 days and washed with 1% KOH for 1 day to remove excess staining. Skeletons were transferred to glycerol and photographed using Zeiss Stemi 305 CAM Digital Stereo Zoom Microscope (Carl Zeiss, Inc, Thornwood, NY).

Flow cytometry

Freshly isolated single-cell suspensions were prepared from the spleens, lymph nodes, bone marrow, and tumor masses. Red blood cells were lysed using ammonium–chloride–potassium (ACK) lysis buffer. Cells were stained with BioLegend antibodies for 30 min in 100 μl volume. Total B-cells (CD19+ B220+), myeloid cells (CD11b+CD5+), mature CD4+ T-cells (CD4+CD3+), and mature CD8+ T-cells (CD8+CD3+) were analyzed in spleen. Tumor burden in Dnmt3bCI/CI, Myc;Dnmt3bCI/CI, MYC;Dnmt3bΔ/Δ, and MYC;Dnmt3bCI/CI mice was evaluated using CD4+ and CD8+ antibodies for PTCL and MTCL or CD19+, CD5+, IgM, and IgD antibodies for CLL and CD11b+ for myeloproliferation. Data were acquired on the LSRFortessa flow cytometers (BD Biosciences, San Diego, CA, USA) and analyzed with FACSDiva software (BD Biosciences, San Diego, CA, USA).

The analysis of clonality in tumors was performed by using mouse Vβ TCR screening kit (BD PharMingen). Aliquots of cell suspensions isolated from the spleens of terminally sick mice were stained with a panel of mAbs recognizing TCR Vβ chain, including Vβ2, 3, 4, 5.1 and 5.2, 6, 7, 8.1 and 8.2, 8.3, 9, 10b, 11, 12, 13, 14, and 17a TCR per manufacturer’s instruction. Tumors were considered monoclonal if they stained for one TCR.

Combined bisulfite restriction analysis

COBRA was carried out as described previously (52). Briefly, bisulfite conversion of genomic DNA was carried out using the
Epitect Bisulfite Kit (Qiagen). PCR products were digested with restriction enzymes BstIII, TaqI, or Tail (NEB). Digested products were then loaded on an 8% PAGE gel, separated by electrophoresis, and stained by SYBR Gold (Invitrogen). Mouse bisulfite specific primers are shown in Supporting Information 5.

**WGBS and bioinformatic analysis**

The WGBS libraries were prepared and sequenced on an Illumina NovaSeq6000 sequencer using 150 bp long paired-end reads (Novogen, USA). Publicly available WGBS data for mouse thymus control were obtained from ENCODE (Joe Ecker, Salk lab, ENCSR001MFH) (40). Quality check, trimming, filtering, and alignment of reads to the *Mus musculus* UCSC mm10 reference genome were performed at the ICBR Bioinformatics Core (UF, Florida). The aligned BAM files were uploaded to the Galaxy web platform (53). Methylation calling was performed with MethylDackel (v 0.3.0.1) using the mm10-CG index (https://github.com/dpryan79/MethylDackel.git). Only CpG sites with a minimum sequencing depth 5x were included in analysis. Methylation scores were visualized with the Integrated Genome Browser (IGB) (54). Scatter plots of methylation score were generated in Rstudio v1.1.4.6 using package ggplot2. Genome-wide Pearson correlation analysis of CpG sites was performed using deepTools package multiBigWigsumary and plotCorrelation (55). Differentially methylated cytosines (DMCs) and differentially methylated regions (DMRs) were determined by Metilene (56). DMCs are defined as CpGs with methylation change of ≥30%. DMRs were defined based on average of minimum three consecutive DMCs with methylation change in the same direction ≥30% (p(MWU) < 0.05). Maximal base pair cutoff for a distance between consecutive DMCs in DMR was set to 50 bp. Annotation of methylated CpGs and DMRs to long promoters, core promoters, exons, introns, CGIs, enhancers, and repeats was performed using bedtools intersect. The DMR was retained if the overlap between these elements and DMR was at least 50% of the length of the DMR. Chromosomal coordinates of TSS, gene bodies, exons, introns, CGIs, and repeats were acquired from the UCSC Table browser. Coordinates of enhancers identified in CD4+CD8+ cells and enhancers cells were obtained from Enhancer atlas (57). Long promoter was defined as 1500 bp upstream to 500 bp downstream of the TSS. Core promoter was defined as 300 bp upstream to 150 bp downstream of the TSS.

**ChIP-seq data analysis**

Publicly available data on chromatin modifications in mouse thymus from 8-week-old mice were obtained from ENCODE (Bing Ren, UCSB lab and John Stamatoyannopoulos, UW; ENCSR325LOF) (40). Heat map of DNAse I sensitivity assay for genes with hypomethylated promoters that become upregulated in *Dnmt3b<sup>−/−</sup>* and/or *Dnmt3a<sup>Δ/A</sup>* lymphomas show unscaled region from −2000 bp to +2000 bp around TSS.

**RNA-seq**

Library generation and sequencing were performed on NovaSeq 6000 platform using paired-end 150 bp runs (Novogene, USA). Previously published RNA-seq data for mice lymphomas driven by conditional loss of Dnmt3a (*EμSra-tTA;Teto-Cre;Dnmt3a<sup>Δ/B</sup>;Ros- sa26LOXP<sup>flox/+</sup>* (36, 39) or expression of human MYC oncogene (16) (*EμSra-tTA;Teto-MYC*) and control CD8+ T-cells (36) were added to analysis. Trimmed sequencing data were first aligned to *Mus musculus* UCSC mm10 reference genome using STAR aligner. RNA-seq data with minimum mapped quality 50 were quantified using the RNA-seq quantitation pipeline in SeqMonk software (http://www.bioinformatics.babraham.ac.uk/projects/seqmonk/). DeSeq2 was used to calculate differential expression. For differentially expressed genes, only genes with a fold change ≥2 and a p value <0.05 were considered to be significant. Reactome and Panther pathway analysis was conducted using WebGestalt (58). Ingenuity pathway analysis (Qiagen) (59) was used to analyze activated and decreased signaling pathways. Hierarchical clustering was performed in Cluster 3.0 (60), and heat maps were visualized in Java TreeView 3.0.

**Gene set enrichment analysis**

All FPKM values for *Dnmt3b<sup>−/−</sup>;Dnmt3a<sup>Δ/A</sup>* lymphomas and control CD8+ T-cells were converted to GCT expression data set. CLS files were generated using CLSFileCreator (v4) (http://software.broadinstitute.org/cancer/software/genepattern/modules/docs/ClSFileCreator/4). All hallmark genes were downloaded from Broad Institute’s Molecular Signatures Database. GSEA (v3.0) (61, 62) was used to test the relationship between RNA-seq expression data and the All hallmarks gene set. Gene sets enriched in less than 15 genes and more than 500 genes were excluded from the analysis. Gene sets with a false discovery rate (FDR) value <0.25 and p <0.05 after performing 1000 permutations were considered to be significantly enriched.

**Western blotting**

Western blots were performed as previously described (31), using the following antibodies: Dnmt1 (sc271729, Santa Cruz; dilution 1:10,000), p53 (sc6243, Santa Cruz; dilution 1:1000), Hsc70 (sc-7298, Santa Cruz; dilution 1:10,000), Dnmt3b (PA1-884, Thermo Fisher; dilution 1:1000), and/or TaiI (NEB). Digested **CNS** products were then loaded on an 8% PAGE gel, separated by electrophoresis, and stained by SYBR Gold (Invitrogen). Mouse bisulfite specific primers are shown in Supporting Information 5.

**Editors’ Pick: Dnmt3b's haploinsufficiency drives lymphomagenesis**

All mRNA was isolated as described previously (31) from *Dnmt3b<sup>−/−</sup>* and *Dnmt3a<sup>Δ/C</sup>* liver. RNA was reverse transcribed with the SuperScript III Reverse transcriptase (Thermo Fisher) using oligo(dT) primers. Real-time qRT-PCR was performed with the iQ SYBR Green Supermix (Bio-Rad) on a CFX96 Touch Real-Time PCR Detection System (Bio-
Rad). Fast PCR cycling conditions were used (95 °C for 3 min, 40 cycles (95 °C for 10 s, 58–63.5 °C for 30 s)), followed by a dissociation curve analysis. All qPCR measurements were performed in duplicate reactions and normalized to the expression of housekeeping gene (β-actin). In parallel, no-RT controls were amplified to rule out the presence of contaminating genomic DNA. Primer sequences for qPCR are provided in Supporting Information 5.

Statistical analysis
Statistical significance of means ± SEM was evaluated using the two-tailed Student’s t-test. For all statistical analyses, p values <0.05 were considered significant. The significance between observed and expected genotype representation of Dnmt3b+/CI and Dnmt3bCI/CI mice was calculated using Chi-squared test. Differential histone enrichment was analyzed by Student’s t-test or Welch’s unequal variances t-test.

Data Availability
All relevant data are available from the corresponding author upon reasonable request. The WGBS and RNA-seq data were deposited at the NCBI Gene Expression Omnibus database [GSE154270, GSE154451, GSE78146] (63).

Acknowledgments—The authors thank the Flow Cytometry and Bioinformatics core facilities of the Interdisciplinary Center for Biotechnology Research at the University of Florida. Mice expressing catalytically inactive Dnmt3b were generated in collaboration with Cyagen Inc. This study was supported by Department of Anatomy and Cell Biology and Cancer Center at the University of Florida start-up funds.

Author contributions—K. L., P. N., J. O., and R. O. contributed to the data generation, editing and writing of the manuscript; A. A. contributed to the data generation and editing; A. R. contributed to the gene expression and DNA methylation processing; S. H. contributed to the data generation; R. O. supervised the project; K. L., P. N., J. O., A. A., A. R., S. L. H., and R. O., read and approved the final manuscript.

Funding and additional information—This study was supported by NIH/NCI grant 1R01CA188561-01A1 (R.O.).

Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations—The abbreviations used are: AF, accessory function; BCLs, B-cell lymphomas; CA, catalytic activity; CLL, chronic lymphocytic leukemia; COBRA, combined bisulfite restriction analysis; CTCs, cutaneous T-cell lymphomas; DMCs, differentially methylated cytosines; DMRs, differentially methylated region; DNMTs, DNA methyltransferases; GSEA, gene set enrichment analysis; HDACs, histone deacetylases; ICF, immunodeficiency, centromeric instability, and facial anomalies syndrome; IPA, ingenuity pathway analysis; MBL, monoclonal B-cell lymphocytosis; MPD, myeloproliferative disease; MTCL, MYC-induced T-cell lymphomas; PTCL, peripheral T-cell lymphoma; PTCL-NOS, peripheral T-cell lymphoma—not otherwise specified; T-ALL, T-cell acute lymphoblastic leukemia; TCL, T-cell lymphoma; TS, tumor suppressor; TSS, transcription start site; WAT, white adipose tissue; WGBS, whole genome bisulfite sequencing.

References
1. Zhang, T., Cooper, S., and Brockdorff, N. (2015) The interplay of histone modifications - writers that read. EMBO Rep. 16, 1467–1481
2. Zhang, Y., Charlton, J., Karnik, R., Beerman, L., Smith, Z. D., Gu, H., Boyle, P., Mi, X., Clement, K., Pop, R., Gnirke, A., Rossi, D. J., and Meissner, A. (2018) Targets and genomic constraints of ectopic Dnmt3b expression. Elife 7, e40757
3. Neri, F., Rapelli, S., Krepeolova, A., Incarnato, D., Parlato, C., Basile, G., Maldotti, M., Anselmi, F., and Oliviero, S. (2017) Intragenic DNA methylation prevents spurious transcription initiation. Nature 543, 72–77
4. McCabe, M. T., Brandes, J. C., and Vertino, P. M. (2009) Cancer DNA methylation: Molecular mechanisms and clinical implications. Clin. Cancer Res. 15, 3927–3937
5. Celik, H., Kramer, A., and Challen, G. A. (2016) DNA methylation in normal and malignant hematopoiesis. Int. J. Hematol. 103, 617–626
6. Wierda, R. J., Geutskens, S. B., Jukema, J. W., Quax, P. H., and van den Elsen, P. J. (2010) Epigenetics in atherosclerosis and inflammation. J. Cell Mol. Med. 14, 1225–1240
7. Rice, K. L., Hormaeche, I., and Licht, J. D. (2007) Epigenetic regulation of normal and malignant hematopoiesis. Oncogene 26, 6697–6714
8. Jones, P. A., and Baylin, S. B. (2007) The epigenomics of cancer. Cell 128, 683–692
9. Okano, M., Bell, D. W., Haber, D. A., and Li, E. (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99, 247–257
10. Li, E., Bestor, T. H., and Jaenisch, R. (1992) Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69, 915–922
11. Jones, P. A., and Liang, G. (2009) Rethinking how DNA methylation patterns are maintained. Nat. Rev. Genet. 10, 805–811
12. Ooi, S. K., Qiu, C., Bernstein, E. Li, K., Jia, D., Yang, Z., Erdjument-Bromage, H., Tempst, P., Lin, S. P., Allis, C. D., Cheng, X., and Bestor, T. H. (2007) DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 448, 714–717
13. Barau, J., Teissandier, A., Zamudio, N., Roy, S., Nalesso, V., Hérault, Y., Guillou, F., and Bourc’his, D. (2016) The DNA methyltransferase DNMT3C protects male germ cells from transposon activity. Science 354, 909–912
14. Bachman, K. E., Rountree, M. R., and Baylin, S. B. (2001) Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin. J. Biol. Chem. 276, 32282–32287
15. Fukai, F., Burgers, W. A., Godin, N., Kasai, M., and Kouzarides, T. (2001) Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J. 20, 2536–2544
16. Haney, S. L., Hlady, R. A., Opavskas, I., Klinkebiel, D., Pirruccello, S. L., Dutta, S., Datta, K., Simpson, M. A., Wu, L., and Opavsky, R. (2015) Methylation-independent repression of Dnmt3b contributes to oncogenic activity of Dnmt3a in mouse MYC-induced T-cell lymphomagenesis. Oncogene 34, 5436–5446
17. Nowialis, P., Lopusna, K., Opavskas, I., Haney, S. L., Abraham, A., Sheng, P., Riva, A., Natarajan, A., Guryanova, O., Simpson, M., Hlady, R., Xie, M., and Opavsky, R. (2019) Catalytically inactive Dnmt3b rescues mouse embryonic development by accessory and repressive functions. Nat. Commun. 10, 4374
18. Duyjmich, C. E., Charlet, J., Yang, X., Jones, P. A., and Liang, G. (2016) Dnmt3B isoforms without catalytic activity stimulate gene body methylation as accessory proteins in somatic cells. Nat. Commun. 7, 11453
19. Baubec, T., Colombo, D. F., Wirbelauer, C., Schmidt, J., Burger, L., Krebs, A. R., Akalin, A., and Schübel, D. (2015) Genomic profiling of DNA methyltransferases reveals a role for Dnmt3b in genomic methylation. Nature 520, 243–247
20. Blanco-Betancourt, C. E., Moncla, A., Milli, M., Jiang, Y. L., Viegas-Péquignot, E. M., Roquelaure, B., Thuret, I., and Schiff, C. (2004)
Defective B-cell-negative selection and terminal differentiation in the ICF syndrome. *Blood* **103**, 2683–2690

21. Franceschini, P., Martino, S., Ciocchini, M., Ciuti, E., Vardeu, M. P., Gual, A., Signorile, F., Camerano, P., Franceschini, D., and Tovo, P. A. (1995) Variability of clinical and immunological phenotype in immunodeficiency-centromeric instability-facial anomalies syndrome. Report of two new patients and review of the literature. *Eur. J. Pediatr.* **154**, 840–846

22. Xu, G., Bestor, T. H., Bourc

23. Kiel, M. J., Sahasrabuddhe, A. A., Rolland, D. C. M., Velusamy, T., Chung, F., Schaller, M., Bailey, N. G., Betz, L. B., Miranda, R. N., Porcu, P., Byrd, J. C., Medeiros, L. J., Kunkel, S. L., Bahler, D. W., Lim, M. S., *et al.* (2015) Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome. *Nat. Commun.* **6**, 6470–6481

24. Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., Corbett, R. D., Johnson, N. A., Severson, T. M., Chiu, R., Field, M., Jackman, S., Krzywinski, M., Scott, D. W., Trinh, D. L., Tamura-Wells, J., *et al.* (2011) Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. *Nature* **476**, 298–303

25. Upchurch, G. M., Haney, S. L., and Opavsky, R. (2016) Aberrant promoter hypomethylation in CLL: Does it matter for disease development? *Front Oncol.* **6**, 182

26. Peters, S. L., Hlday, R. A., Opavsky, J., Klinkebien, D., Pirruccello, S. J., Talmon, G. A., Sharp, J. G., Wu, L., Jaenisch, R., Simpson, M. A., Karpf, A. R., and Opavsky, R. (2014) Tumor suppressor functions of Dnmt3a and Dnmt3b in the prevention of malignant mouse lymphopoesis. *Leukemia* **28**, 1138–1142

27. Haferlach, T., Kohlmann, A., Wieczorek, L., Basso, G., Kronrie, G. T., Hendrick, C., Ostler, K. R., Davis, E. M., Lin, S., Anastasi, J., Le Beau, M., and Opavsky, R. (2014) Dnmt3a is a haploinsufficient tumor suppressor in CD8+ peripheral T cell lymphoma. *Plos Genet.* **12**, e1006334

28. Consortium, E. P. (2012) An integrated encyclopedia of DNA elements in the human genome. *Nature* **489**, 57–74

29. Donehower, L. A., Harvey, M., Vogel, H., McArthur, M. J., Montgomery, C. A., Park, S. H., Thompson, T., Ford, R. J., and Bradley, A. (1995) Effects of genetic background on tumorigenesis in p53-deficient mice. *Mol. Carcinog.* **14**, 16–22

30. van der Weyden, L., Rust, A. G., McIntyre, R. E., Robles-Espinoza, C. D., del Castillo Velasco-Herrera, M., Strogantsev, R., Ferguson-Smith, A. M., McCarthy, S., Keane, T. M., Arends, M. J., and Adams, D. J. (2013) Idp2 downregulates Trp53 transcription to promote leukaemogenesis in the context of Trp53 heterozygosity. *Oncogene* **32**, 397–402

31. Lu, S., Qian, J., Guo, M., Gu, C., and Yang, Y. (2019) Insights into a crucial role of TRP13 in human cancer. *Comput. Struct. Biotechnol. J.* **17**, 854–861

32. Avalle, L., Pensa, S., Regis, G., Novelli, F., and Poli, V. (2012) STAT1 and STAT3 in tumorigenesis: A matter of balance. *JAKSTAT* **1**, 65–72

33. Felsher, D. W., and Bishop, J. M. (1999) Reversible tumorigenesis by MYC in hematopoietic lineages. *Cell* **4**, 199–207

34. Cole, C. B., Russler-Germain, D. A., Ketkar, S., Verdoni, A. M., Smith, A. M., Bangert, C. V., Hengel, N. M., Guo, M., Kloc, J. M., O’Laughlin, S., Fronick, C., Fulton, R., Chang, G. S., Petti, A. A., Miller, C. A., *et al.* (2017) Haploinsufficiency for DNA methyltransferase 3A predisposes hematopoietic cells to myeloid malignancies. *J. Clin. Invest. 127*, 3657–3674

35. Hwang, H. C., Martins, C. P., Bronkhorst, Y., Ranel, D., Berns, A., Fero, M., and Clurman, B. E. (2002) Identification of oncogenes collaborating with p27kip1 loss by insertional mutagenesis and high-throughput insertion site analysis. *Proc. Natl. Acad. Sci. U. S. A.* **99**, 11293–11298

36. Kovacic, B., Stoiber, D., Moriggl, R., Weisz, E., Ott, R. G., Kreibich, R., Levy, D. E., Beug, H., Freissmuth, M., and Sexl, V. (2006) STAT3 in tumorigenesis: A matter of balance. *Mol. Cell* **15**, 159–177

37. Vanasathanakum, A., Lepore, J. B., Zegarek, M. H., Kocherginsky, M., Singh, M., Davis, E. M., Link, P. A., Anastasi, J., Le Beau, M. M., Karpf, A. R., and Godley, L. A. (2013) Dnmt3b is a haploinsufficient tumor suppressor gene in Myc-induced lymphomagenesis. *J. Clin. Invest.* **122**, 163–177

38. Vanasathanakum, A., Barnes, N. Y., Figueroa, M. E., Kamp, A., Hendrick, C., Ostler, K. R., Davis, E. M., Lin, S., Anastasi, J., Le Beau, M. M., Moskowitz, I. P., Melnick, A., Pytel, P., and Godley, L. A. (2010) Dnmt3b deficiency drives lymphomagenesis in mouse embryonic stem cells. *Cell Rep.* **17**, 289–302

39. Sterlin, D., Velasco, G., Moschous, D., Tourzot, F., Mahlaouli, N., Fischer, A., Suarez, F., Francais, C., and Picard, C. (2016) Genetic, cellular and clinical features of ICF syndrome: A French National Survey. *Leukemia* **30**, 2373–2384

40. Poole, C. J., Zheng, W., Lodh, A., Yevdoviyenko, A., Liefdwalser, D., Li, H., Felsher, D. W., and van Riggelen, J. (2017) Dnmt3b overexpression contributes to aberrant DNA methylation and MYC-driven tumor maintenance in T-ALL and Burkitt’s lymphoma. *Oncoarget 8*, 76898–76920

41. Haney, S. L., Upchurch, G. M., Opavsky, J., Klinkebien, D., Hlday, R. A., Suresh, A., Pirruccello, S. J., Shukla, V., Lu, R., Costinean, S., Rizzino, A., Karpf, A. R., Joshi, S., Swanson, P., and Opavsky, R. (2016) Promoter hypomethylation and expression is Conserved in mouse chronic lymphocytic leukemia induced by decreased or inactivated Dnmt3a. *Cell Rep.* **15**, 1190–1201

42. Xiao, H., and Kang, S. (2019) The role of DNA methylation in thymic adipo lineage. *Epigenetics* **14**, 837–843

43. Stratikopoulos, E., Szabolcs, M., Daravis, I., Klinakis, A., and Efstrati- dis, A. (2008) The hormonal action of IGFI in postnatal mouse growth. *Proc. Natl. Acad. Sci. U. S. A.* **105**, 19378–19383

44. Haney, S. L., Upchurch, G. M., Opavsky, J., Klinkebien, D., Hlday, R. A., Roy, S., Dutta, S., Datta, K., and Opavsky, R. (2016) Dnmt3a is a haploinsufficient tumor suppressor in CD8+ peripheral T cell lymphoma. *Plos Genet.* **12**, e1006334

45. provincia, J. M., Lewis, R. E., Karpf, A. R., Simpson, M. A., Wu, L., and Opavsky, R.
(2013) Essential role for Dnmt1 in the prevention and maintenance of MYC-induced T-cell lymphomas. *Mol. Cell Biol* **33**, 4321–4333

53. Afgan, E., Baker, D., Batut, B., van den Beek, M., Bouvier, D., Cech, M., Chilton, J., Clements, D., Coraor, N., Grüning, B. A., Guerler, A., Hillman-Jackson, J., Hiltemann, S., Jalili, V., Rosche, H., *et al.* (2018) The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. *Nucleic Acids Res.* **46**, W537–W544

54. Nicol, J. W., Helt, G. A., Blanchard, S. G., Raja, A., and Loraine, A. E. (2009) The Integrated Genome Browser: Free software for distribution and exploration of genome-scale datasets. *Bioinformatics* **25**, 2730–2731

55. Ramírez, F., Ryan, D. P., Grüning, B., Bhardwaj, V., Kilpert, F., Richter, A. S., Heyne, S., Dündar, F., and Manke, T. (2016) deepTools2: A next generation web server for deep-sequencing data analysis. *Nucleic Acids Res.* **44**, W160–165

56. Jühling, F., Kretzmer, H., Bernhart, S. H., Otto, C., Stadler, P. F., and Hoffmann, S. (2016) metilene: Fast and sensitive calling of differentially methylated regions from bisulfite sequencing data. *Genome Res.* **26**, 256–262

57. Gao, T., He, B., Liu, S., Zhu, H., Tan, K., and Qian, J. (2016) Enhancer-Atlas: A resource for enhancer annotation and analysis in 105 human cell/tissue types. *Bioinformatics* **32**, 3543–3551

58. Liao, Y., Wang, J., Jaehnig, E. J., Shi, Z., and Zhang, B. (2019) WebGestalt 2019: Gene set analysis toolkit with revamped UIs and APIs. *Nucleic Acids Res.* **47**, W199–W205

59. Krämer, A., Green, J., Pollard, J., and Tugendreich, S. (2014) Causal analysis approaches in Ingenuity pathway analysis. *Bioinformatics* **30**, 523–530

60. de Hoon, M. J., Imoto, S., Nolan, J., and Miyano, S. (2004) Open source clustering software. *Bioinformatics* **20**, 1453–1454

61. Mootha, V. K., Lindgren, C. M., Eriksson, K. F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., Housted, N., Daly, M. J., Patterson, N., Mesirov, J. P., Golub, T. R., *et al.* (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat. Genet.* **34**, 267–273

62. Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., and Mesirov, J. P. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 15545–15550

63. Edgar, R., Domrachev, M., and Lash, A. E. (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. *Nucleic Acids Res.* **30**, 207–210

Dr. Katarina Lopusna conducted most of her recent research on characterization of tumorigenic processes in hematologic malignancies as a postdoctoral associate at the University of Florida. She continues her research at the Department of Viral Immunology, Biomedical Research Center, Slovak Academy of Sciences, Slovakia, focusing on immune checkpoint regulators and how these could be modulated to treat cancer. She can be found at [https://www.researchgate.net/profile/Katarina_Lopusna](https://www.researchgate.net/profile/Katarina_Lopusna)

Dr. Pawel Nowialis is a postdoctoral associate at the Department of Anatomy and Cell Biology, University of Florida College of Medicine, Gainesville, USA. He has always been drawn to the research with relevance to human health. Recently, he focused on studying the role of DNA methylation in normal and malignant hematopoiesis. He can be found at [https://www.researchgate.net/profile/pawel-nowialis](https://www.researchgate.net/profile/pawel-nowialis)